Lorlatinib - Induced pulmonary arterial hypertension
- PMID: 29748016
- DOI: 10.1016/j.lungcan.2018.03.023
Lorlatinib - Induced pulmonary arterial hypertension
Abstract
We report here the first cases, to our knowledge, of pulmonary arterial hypertension induced by lorlatinib. It s the first time that a tyrosine kinase inhibitor for lung cancer is associated with pulmonary arteriel hypertension.
Keywords: ALK rearrangement; Lorlatinib; Lung cancer; Pulmonary hypertension; Tyrosine kinase inhibitor.
Copyright © 2018 Elsevier B.V. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources